Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing by Collet, J-P et al.
Evidence that non-steroidal anti-inflammatory drugs (NSAIDs)
prevent colorectal adenocarcinoma comes from numerous animal
(Pollard and Luckert, 1981; Birkenfeld et al, 1987) and human
studies, which include cohort studies, case—control studies, and
one randomized clinical trial. Most have shown that NSAIDs have
protective effects with rate ratios from 0.7 to 0.2. However, one
cohort study found an excess risk in the elderly exposed to aspirin
(Paganini-Hill et al, 1989) and the only randomized clinical trial
(Gann et al, 1993) showed no effect after 5 years of follow-up.
Case—control studies have been limited by poor recall of
exposure. Recently, however, Pelleg et al (1996) used a hospital
drug database to assess exposure. Although they found a strong
dose-dependent protective effect, the results were difficult to inter-
pret because the study was hospital-based and the controls were
selected randomly without considering their admission diagnoses.
Cohort studies may have been less prone to problems of expo-
sure assessment. In most of these studies, however, exposure was
limited to an estimate of exposure at entry based on data obtained
by interview or self-administered questionnaire (Paganini-Hill
et al, 1989; Thun et al, 1991; Gridley et al, 1993; Schreinemachers
and Everson 1994). Only two collected information repeatedly to
study the effects of dose and duration of exposure to NSAIDs
(Giovannucci et al, 1994c, 1995). Giovannucci et al (1995) found
a protective effect (rate ratio = 0.63, 95% confidence interval (CI)
0.42—0.94) among women who took ‡ 2 aspirin tablets per week
for ‡ 10 years. They did not find a dose—response relationship and
concluded that benefit may not appear until after a decade of
regular use.
Do similar exposures at different times have similar or different
effects? To answer this question in relation to the prevention of
colorectal cancer by drug exposure the combined induction and
latent periods for the drugs studied must be determined, i.e. the time
which must pass before the preventive effect of an exposure will
become detectable. Failure to do so will dilute the measured effect
of exposure. For example, cumulative exposure may include both
aetiologically relevant remote use that could have an effect
on disease incidence at a specific time, as well as aetiologically irrel-
evant recent use that could not have any effect because the induction
and latent periods have not yet elapsed (Rothman, 1981).
To study the effects of dose and the timing of NSAID use we
carried out a population-based case—control study, nested in a non-
concurrent cohort linkage study in Saskatchewan, using pre-
recorded data collected routinely by the Saskatchewan Cancer
Agency (SCA) and the Saskatchewan Prescription Drug Plan
(SPDP; operating since 1975). These agencies provide universal
coverage to the Saskatchewan population. This offered us an
opportunity to carry out a study with minimal potential for selec-
tion and recall bias and gave us drug exposure histories of suffi-
cient length to determine the effects of dose and the timing of
NSAID use on the risk of colorectal cancer.
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Summary Epidemiological studies show that non-steroidal anti-inflammatory drugs (NSAIDs) reduce colorectal cancer incidence. We
measured the rate ratio for colorectal adenocarcinoma according to dosage and the timing of exposure by means of a case–control study,
nested in a non-concurrent cohort linkage study, using the population of beneficiaries of the Saskatchewan Prescription Drug Plan from 1981
to 1995 with no history of cancer since 1970 as the source population. Four controls per case, matched on age and gender and alive when
the case was diagnosed, were randomly selected. Dispensing rates, calculated over successive time periods, characterized NSAID
exposure. We accrued 3844 cases of colon cancer and 1971 cases of rectal cancer. For colon cancer a significant trend towards a decreasing
rate ratio was associated with increasing exposure during the 6 months preceding diagnosis (P-trend = 0.002). For both cancers, significant
trends were associated with exposure 11–15 years before diagnosis (colon: P-trend = 0.01; rectum: P-trend = 0.0001). At the highest
exposure levels the rate ratio for colon cancer was 0.57 (95% confidence interval (CI) 0.36–0.89); for rectal cancer it was 0.26 (95% CI
0.11–0.61). No protection was associated with exposure during other periods. The timing of NSAID use must be considered in planning
intervention trials to prevent colorectal cancer. There may be a 10-year delay before any preventive effect will appear.
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SUBJECTS AND METHODS
Definitions of study populations
We defined a source population for the study from which we
sampled cases and controls. It was the open population of men and
women aged 35 years or older who were eligible to receive bene-
fits from the SPDP during 1981 to mid-1995, with no history of
cancer since 1970 other than non-melanoma skin cancer or carci-
noma in situ of the cervix. Earlier cancer diagnoses were unavail-
able, because the records of the SCA were not computerized prior
to 1970.
Subjects entered the source population on 1 January 1981 if
they were aged 35 or older, or on their 35th birthday, or on the date
of immigration into the province if aged 35 years or older,
whichever occurred latest. Subjects left the source population on
30 June 1995, on the date of diagnosis of colorectal cancer or of
death, or on the date of emigration, whichever occurred first.
The SPDP pays for prescription drugs for 94% of the
Saskatchewan population (1.01 million people in mid-1991)
(Rawson et al, 1992). Military personnel and aboriginals, who are
covered by federal agencies, are excluded. Immigrants become
eligible to benefit 3 months after arriving, which is recorded as the
coverage initiation date. Emigrants lose their eligibility 3 months
after leaving. Emigration from a population similar to that of this
study was estimated to be < 0.8% per year (Risch and Howe,
1994). Every person eligible to receive benefits is issued with a
plastic card on which is stamped a unique personal identification
number which can be used to identify the same individual over
time in the same database and across different databases, including
that of the SCA. Until the end of 1990 the personal identification
number consisted of eight digits; since 1991 it consisted of nine
digits, one of them representing the sum of other digits so that the
validity of the entire identification number can be checked
(Rawson et al, 1992). The nine digit identification numbers are
also encoded in a magnetic strip on beneficiaries￿ plastic cards, so
that services can be registered electronically. The accuracy of the
identifying information used by the SPDP exceeds 99.99% and the
accuracy of the recorded prescription information exceeds 99%
(Risch and Howe, 1994).
The cases were defined as subjects in the source population who
were diagnosed with histologically proven adenocarcinoma of the
colon or rectum and reported to the SCA. Registration of cancer
cases was likely to be nearly complete because physicians￿ claims
for services are paid only for registered cases and copies of all
malignant pathology reports are sent to the SCA. These two mech-
anisms of notification cover approximately 98% of all new cancer
cases diagnosed within the province; an additional 1—2% of cases
are discovered through death certificates received biweekly
(Parkin et al, 1997). To be included in our study cases must have
been eligible to benefit from the SPDP for at least 5 years before
diagnosis; this was to ensure that sufficiently long records of their
drug use, if any, would be available for analysis. Hereafter, the
date of diagnosis will be designated as the ￿index date￿.
Potential controls were defined as the subjects in the source
population of the same age (expressed as an integral number of
years) and gender as the case to whom they were individually
matched and who were alive on the date upon which the case was
diagnosed and therefore at risk of developing colorectal cancer.
The date of diagnosis for each case was assigned to each of the
matched potential controls as their index date, thereby matching
cases and controls on sampling time as well (Rothman and
Greenland, 1998). Like the cases, the controls must have been
eligible to benefit from the SPDP for at least 5 years before the
index date.
Linkage methods
Information pertaining to individuals registered in the databases of
the SPDP and the SCA was linked by matching personal identi-
fiers. Subjects accrued from 1 January 1981 until 31 December
1990 had their records linked on the basis of an exact match of
three variables: the eight digit personal identification number, the
year of birth (±2 years, because of inconsistent reporting of the
year of birth by some very old subjects), and gender. Subjects
accrued after 1 January 1991 had their records linked on the basis
of an exact match of the nine-digit personal identification number.
Methods of selection of cases and controls
Computerized lists of all cases of histologically proven adenocar-
cinoma of the colon or rectum aged 35 years or more at diagnosis
with no history of cancer since 1970, other than non-melanoma
skin cancer and carcinoma in situ of the cervix, reported to the
SCA as having been diagnosed from 1 January 1981 until 30 June
1995, were obtained. These lists from the SCA were cross-refer-
enced against the database of the SPDP using the linkage proce-
dures described above. Cases whose coverage initiation dates for
the SPDP preceded their index dates by less than 5 years were then
excluded. In selecting the cases we were blind to the nature of
which drugs they took, if any, during their exposure histories.
For each selected case, the SPDP database was searched to
compile a separate computerized list of individually matched
potential controls. All the potential controls on each list were of
the same age and gender as the case and were alive on the case￿s
index date. Potential controls whose coverage initiation dates for
the SPDP preceded their index dates by less than 5 years were then
excluded from each list. As with the cases, we were blind to the
nature of which drugs they took, if any, during their exposure
histories. These lists were then cross-referenced against the SCA
database using the linkage procedures described above to deter-
mine the date of diagnosis of every cancer, if any, diagnosed in
each potential control back to 1970. Subjects with cancer diag-
noses, other than non-melanoma skin cancer and carcinoma in situ
of the cervix, that occurred before the index date of the case to
whom they were matched were then excluded from each list. Each
list was then sampled randomly without replacement so that four
controls per case were selected. This method of selecting controls
is known as risk-set sampling (Rothman and Greenland, 1998).
Drug exposure data
For all subjects drug exposure data were obtained from the SPDP
database which provided information for the period between the
index date back to January 1 1976 or the coverage initiation date,
whichever was later. The drug exposure histories ranged from 5 to
19.5 years in length.
For each prescription for NSAIDs dispensed to a subject as an
outpatient, the following information was recorded: the subject￿s
unique identification number, the dispensing date, the class and
identity of the drug according to the American Hospital Formulary
System classification, the number of doses dispensed, and the64 J-P Collet et al
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strength (mg per pill). The number of pills per day recommended
and the duration of treatment were not available.
Information was also obtained about other drugs that could
confound the exposure—disease relationship, e.g. drugs used in the
treatment of inflammatory bowel disease and oestrogens.
No data on any drugs prescribed during hospitalizations or
during the period 1 July 1987 to 1 January 1989 were available,
because the SPDP did not record the dispensing of drugs to indi-
viduals during that period. The database also lacks information on
drugs given directly to patients by physicians as samples and drugs
bought without prescriptions. Aspirin and ibuprofen can be bought
without prescriptions, the latter since August 1989.
Confidentiality
The extraction of the data from the electronic databases of the
SCA and the SPDP was carried out by employees of the SCA and
Saskatchewan Health. The data delivered for analysis were devoid
of any information that could be used to identify anyone. No
subjects were contacted to obtain information. The study was
approved by the ethics committees of the Sir Mortimer B
Davis—Jewish General Hospital, Montreal, the Cross Agency
Study Committee of Saskatchewan Health, Regina, and the
Internal Review Board of the SCA.
Data analysis
We analysed exposure to NSAIDs as a class rather than exposure
to individual drugs, recognizing that NSAIDs in general reduce
the risk of colorectal cancer (Berkel et al, 1996). This strategy
provided the analysis with sufficient power to study the effects of
timing of exposure because the numbers of subjects with histories
of use of any one drug were relatively small.
To study the effects of the timing of exposure we decided a
priori to divide time preceding the index date into successive
5-year periods. The period immediately preceding the index date
was divided further into two 6-month periods and the preceding
4-year period. The periods were: 1—6 months, 7—12 months,
2—5 years, 6—10 years and 11—15 years.
Exposure was characterized in terms of average rates of
dispensing NSAIDs, calculated from the amounts dispensed over
the periods described. Three different methods of calculating
dispensing rates were used and all produced similar patterns of
results. The first two methods were based on the number of either
prescriptions or pills dispensed per year; the results of analyses
using these methods are not shown for brevity. The third method
was based on the proportion of the maximum recommended daily
dose of each NSAIDi dispensed (pi = average mg day—1 dispensed ￿
maximum mg day—1 recommended) (Carson et al, 1987) and was
calculated for each different NSAID used during each period of
time. The sum of the proportions, i.e. Spi for all the NSAIDs
used during a period, was considered as the measure of exposure.
This method distinguished non-users from low levels users
(0 < Spi † 0.1), from medium level users (0.1 < Spi † 0.3), from
high level users (Spi > 0.3). For some high level users Spi
exceeded 1.0. These categories were determined by examining
frequency distributions of Spi. The usual maximum daily dose for
each NSAID was taken from the manufacturers￿ recommendations
(Compendium of Pharmaceuticals and Specialties, 1995). The
drugs, their recommended maximum daily doses, and the total
number of prescriptions of each drug dispensed between the date
on which subjects first became eligible to benefit from the SPDP
and the index date for all subjects are shown in Table 1.
The analysis was designed to deal with missing exposure infor-
mation. Since the overall length of the drug exposure histories
ranged from 5 to 19.5 years, for each subject there was information
missing beyond a certain time in the past. In addition, subjects
whose index dates occurred after 1 July 1987 had their histories
interrupted by the 1.5-year period during which the SPDP database
was incomplete and the use of most drugs was not recorded on an
individual basis. If the drug exposure history for a period was
missing or incomplete, due either to the date of the subject￿s enrol-
ment in the SPDP or to the 1.5-year period of missing information,
the subject was assigned to a separate category designated ￿other￿,
distinct from the referent and the categories of exposure (Breslow
and Day, 1980; Miettinen, 1985). This category can be considered
to represent an indeterminate level of exposure. Because the
maximum length of the exposure histories was 19.5 years, we trun-
cated the exposure histories at 15 years before the index date —
otherwise, all subjects with longer exposure histories would be
categorized in the ￿other￿ category for the preceding
5-year period.
This approach allowed us to retain each subject in the analysis,
the aim of which was to estimate the effects of similar exposures at
different times over a 15-year span, rather than exclude subjects
with missing information. Even though the exposure histories of
many subjects were less than 15 years long and many were inter-
rupted by the 1.5-year gap, subjects contributed information to the
analysis of the effects of NSAID exposure during the periods for
which we had complete exposure information, and no information
to the periods for which we lacked complete information. For
example, subjects who immigrated to Saskatchewan 12.5 years
prior to their index date would contribute no information to the
analysis of the effects of exposure 11—15 years before the index
date, but would contribute information to the periods closer to the
index date, provided they were not interrupted by the 1.5-year gap.
Table 1 Listed are the NSAIDs dispensed to all cases of colon cancer,
rectal cancer and controls between the date on which subjects first became
eligible to receive benefits from the SPDP and each subject’s index date.
Beside each drug is the recommended maximum daily dose and the total
number of prescriptions of each drug dispensed (N)
Drug Usual maximum N
daily dose (Rx)
(mg day–1)
Aspirin 3900 76 867
Diclofenac 150 16 451
Diflunisal 1000 4666
Fenoprofen 2400 10 906
Floctafenene 1200 605
Flurbiprofen 200 577
Ibuprofen 1200 39 619
Indomethacin 200 49 807
Ketoprofen 200 13 501
Mefenamic acid 1000 871
Nabumetone 2000 3
Naproxen 1000 35 251
Phenylbutazone 400 11 995
Piroxicam 20 26 938
Sulindac 400 15 368
Tiaprofenic acid 600 2482
Tolmetin 1800 1424
Zomepirac 400 349We calculated odds ratios to estimate incidence density ratios
(rate ratios) with conditional logistic regression to account for the
individual matching on age, gender and index date (Breslow and
Day, 1980) by means of the SAS PHREG procedure (SAS
Institute, 1992). The results are presented with 95% CIs. The
statistical model that we used to relate the rate ratios to the drug
exposure history over time was:
exp(b1X1—6 mos+b2X7—12 mos+b3X2—5 yrs+ b4X6—10 yrs+b5X11—15 yrs)
where the values of bi represented the regression coefficients, and
the values of Xi represented drug exposure during the successive
periods of time preceding the index date. This approach was based
on Miettinen￿s recognition that exposures during ￿different time
periods represent separate determinants ￿ mutually confounded
and thus requiring joint representation in the same model￿
(Miettinen, 1985). Since NSAIDs are used for chronic conditions
and exposure during one period could be associated with exposure
in another, mutual adjustment for successive periods of exposure
was required.
The rate ratios for a particular period calculated in this way
represented the ratio of the incidence of disease among those
exposed to NSAIDs during that period to the incidence of disease
among those unexposed during that period. The mutual adjustment
for successive periods of exposure provided by the statistical
model permitted us to estimate the effect of varying NSAID expo-
sure during a given period while keeping the pattern of NSAID
exposure during all the other periods identical.
Exposure was represented by categorical variables. There were
five categories of exposure: unexposed (the referent), low,
medium, high and ￿other￿. We did not use Spi as a continuous vari-
able because it was not always linearly related to the log of the rate
ratio.
Testing for trends was carried out by representing the categories
of exposure in the models with ordinal variables, considered as
continuous, and examining the significance of the coefficients
with a c2 test (Breslow and Day, 1980). P-values for interaction
were derived from likelihood ratio tests comparing nested models
with and without interaction terms. We used P < 0.05 (two-sided)
as the criterion of statistical significance.
RESULTS
We accrued 3844 colon cancer cases (1925 males) with 15 373
controls and 1971 rectal cancer cases (1230 males) with 7882
controls. The mean age of the colon cancer cases was 70.8 years
(11.6 standard deviation (s.d.)); for the rectal cancer cases it was
69.4 years (11.6 s.d.).
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Table 2 Rate ratios for colon cancer and for rectal cancer according to NSAID exposure by time period before diagnosis, with adjustment for exposure during
the other time periods
Colon Cancer Rectal Cancer
Period Average Cases Controls RRa 95% CI Cases Controls RRa 95% CI
before daily n = n = n = n =
diagnosis dose 3844 15373 1971 7882
1–6 months 0 2673 10214 1.00 Referent 1372 5373 1.00 Referent
0 <Spi≤0.1 235 871 1.06 0.91–1.24 102 401 1.01 0.80–1.28
0.1<Spi≤0.3 220 1012 0.88 0.75–1.04 115 473 0.99 0.79–1.25
Spi>0.3 167 1080 0.69 0.56–0.86 97 495 0.80 0.59–1.08
P (trend) 0.002 0.26
Other 549 2196 – – 285 1140 – –
7–12 months 0 2667 10175 1.00 Referent 1365 5387 1.00 Referent
0 <Spi≤0.1 197 816 0.93 0.79–1.10 101 374 1.12 0.88–1.41
0.1<Spi≤0.3 233 1014 0.97 0.83–1.15 123 510 1.01 0.81–1.27
Spi>0.3 191 1144 0.85 0.68–1.05 105 503 0.93 0.68–1.25
P (trend) 0.08 0.99
Other 556 2224 – – 277 1108 – –
2–5 years 0 1102 4177 1.00 Referent 648 2446 1.00 Referent
0 <Spi≤0.1 855 3357 0.99 0.89–1.10 420 1842 0.87 0.76–1.00
0.1<Spi≤0.3 193 922 0.90 0.75–1.08 104 421 1.03 0.80–1.32
Spi>0.3 106 566 0.97 0.76–1.24 68 250 1.29 0.94–1.78
P (trend) 0.41 0.80
Other 1588 6351 – – 731 2923 – –
6–10 years 0 766 3022 1.00 Referent 412 1564 1.00 Referent
0 <Spi≤0.1 808 3061 1.07 0.96–1.20 367 1477 0.97 0.83–1.14
0.1<Spi≤0.3 135 638 0.92 0.75–1.13 67 282 0.92 0.69–1.24
Spi>0.3 69 362 0.94 0.71–1.24 28 155 0.77 0.50–1.18
P (trend) 0.75 0.31
Other 2066 8290 0.88 0.61–1.26 1097 4404 0.77 0.46–1.31
11–15 years 0 590 2228 1.00 Referent 303 1047 1.00 Referent
0 <Spi≤0.1 581 2218 1.01 0.88–1.15 235 1016 0.80 0.66–0.98
0.1<Spi≤0.3 67 386 0.73 0.55–0.96 22 125 0.63 0.39–1.01
Spi>0.3 23 181 0.57 0.36–0.89 6 82 0.26 0.11–0.61
P (trend) 0.01 0.0001
Other 2583 10360 0.87 0.64–1.18 1405 5612 0.95 0.62–1.45
aRRs (s) were calculated with conditional logistic regression because of matching for age, gender and index date. Exposure was categorized according to
values of Spi (see Methods – Data Analysis) during the periods indicated. The ‘other’ category was for subjects with incomplete exposure information.66 J-P Collet et al
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Three controls were excluded from the colon cancer study
because their coverage initiation dates for the SPDP occurred after
they entered the source population rather than before, which
suggested that they may have left Saskatchewan and returned later,
their emigration having been unrecorded. Two controls were
excluded from the rectal cancer study for the same reason.
The rate ratio according to ever vs never dispensing of NSAIDs
was 1.00 (95% CI 0.92—1.09) for colon cancer; 74.0% of both the
cases and controls were exposed. For rectal cancer the rate ratio
was 0.90 (95% CI 0.81—1.00); 69.6% of the cases and 71.7% of the
controls were exposed.
Table 2 shows the results of analyses in which NSAID exposure
was defined in terms of Spi calculated for each period, adjusting
for the effects of exposure during the other periods. For colon
cancer there were significant trends towards decreasing rate ratios
associated with increasing NSAID exposure during the 6 months
before the index date (P-trend = 0.002) and during the 11—15 years
before the index date (P-trend = 0.01), with no significant trends in
between. For rectal cancer there was also evidence of a significant
trend towards decreasing rate ratios associated with increasing
NSAID exposure during the 11—15 years before the index date
(P-trend = 0.0001), but not during any other periods. The rate
ratios associated with NSAID exposure did not depend on gender
for either colon cancer (P = 0.33, for interaction) or rectal cancer
(P = 0.35, for interaction).
The regression coefficients for the ￿other￿ exposure category for
the periods preceding the index date by † 5 years could not be
calculated because of insufficient variation: since cases and
controls were matched for index date, if exposure information was
missing for a case, due to the 1.5-year gap in the exposure histories
beginning 1 July 1987, it was always missing for the matched
controls, so they were all classified as ￿other￿ and contributed no
information to the matched analysis.
To determine if the dispensing of other drugs could confound
the relationship between NSAID dispensing and the diagnosis of
colon cancer or rectal cancer we began by determining if the
dispensing of other drugs was also associated with the diagnosis of
either cancer. We considered drugs dispensed to treat inflamma-
tory bowel disease, which is associated with an increased risk of
colorectal cancer (Potter et al, 1993), and oestrogens, which may
be protective (Newcomb and Storer, 1995).
The dispensing of corticosteroids was not associated with the
diagnosis of colon cancer or rectal cancer and so could not lead to
confounding. However, the dispensing of either sulfasalazine
or 5-aminosalicylic acid or both during the year preceding the
index date was strongly associated with the diagnosis of colon
cancer.
Very small numbers of women had exposure to oral contracep-
tives or progestins and there were no dose—response trends.
However, appreciable numbers of women had received oestrogen
replacement therapy and we detected negative associations
between the dispensing of oestrogens during the 11—15 years
before the index date and the diagnosis of both colon and rectal
cancer.
To control possible confounding by exposure to sulfasalazine,
5-aminosalicylic acid, or oestrogen replacement therapy, we
repeated the analyses shown in Table 2 after excluding all subjects
with any exposure to either sulfasalazine or 5-aminosalicylic acid
and including terms representing exposure to estrogens over time.
The rate ratios associated with NSAID exposure were almost iden-
tical to those shown in Table 2 for both tumours.
DISCUSSION
Summary of findings
The dispensing of NSAIDs 11—15 years before the index date is
associated with a dose-dependent reduction in the rate ratios for
colon cancer and rectal cancer, using three different measures of
exposure, one of which is shown in Table 2. For colon cancer, but
not for rectal cancer, there was a trend towards a decreasing rate
ratio with increasing dose associated with exposure during the
6 months preceding the index date.
Representation of exposure
We represented exposure to NSAIDs as a class rather than as indi-
vidual drugs. The analysis of the effects of individual drugs would
have been limited by the small numbers of subjects exposed to
each drug. In addition, animal experiments have shown that ￿the
beneficial effect of NSAIDs does not seem to be restricted to one
particular drug￿ (Berkel et al, 1996). The underlying reason may
be that all NSAIDs inhibit prostaglandin synthesis.
Considering exposure during different periods to represent sepa-
rate determinants provided a simple way to represent the exposure
history over time with multiple logistic regression, which allowed
us to study the effects of the timing of exposure (Miettinen, 1985).
The unexposed during each period were the referent for that
period. This was justified by the fact that ingested NSAIDs are
excreted and their pharmacological effects cease when use stops.
Our measures of exposure were based on average rates of
dispensing computed over extended periods, usually 5 years, and
focused on the timing of exposure. We did not study the effects of
overall duration of exposure, since such analyses do not take the
induction and latent periods of the disease into account and
produce attenuated measures of effect, since they include periods
of exposure irrelevant to the outcome (Rothman, 1981). Nor did
we study the effects of duration of exposure within periods
because we lacked information on the length of treatment periods.
Since NSAID use is often intermittent (e.g. for the treatment of
pain due to dysmenorrhea, headaches and injuries), we doubted
that estimating duration of use would be valid.
Collinearity was not an issue in any of the analyses. None of the
absolute values of the correlation coefficients between the regres-
sion coefficients in the analysis of Table 2 were larger than 0.52.
The largest such value for the period 11—15 years before the index
date was only 0.15. When exposures were considered separately
(results not shown), the rate ratios tended to be similar but slightly
more extreme than when included altogether in the models shown.
Since our measures of exposure were limited, being based
solely on prescriptions dispensed to outpatients, it is likely that the
subjects￿ actual consumption of NSAIDs differed somewhat from
our estimates of exposure. On the one hand, it is unlikely that all
the drugs dispensed were ingested: we may have overestimated
exposure. On the other hand, we may have underestimated expo-
sure, since we had no information about NSAIDs dispensed in
hospitals or as samples in physicians￿ offices. These amounts were
likely to be small relative to the amounts we used in calculating
exposure. Nor did we have information about aspirin and
ibuprofen bought over the counter: these amounts were also prob-
ably relatively small, since anyone needing to use appreciable
amounts could request a prescription from a physician and the
SPDP would pay. Subjects in the reference categories may haveColorectal cancer prevention by NSAIDs 67
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had low levels of exposure to either aspirin or ibuprofen or both.
If we overestimated NSAID exposure among those subjects
classified as highly exposed, and underestimated NSAID exposure
among those subjects classified as unexposed, then the slope of the
dose—risk relationship that we observed would be less extreme
than the true slope (MacMahon and Trichopoulos, 1996). It is
possible, however, that the most highly exposed subjects may have
ingested almost all of the NSAIDs dispensed, if they suffered
chronic pain. If we accurately estimated overall NSAID exposure
among the highly exposed and underestimated it among the non-
exposed, then the true dose—risk curve would be shifted to the right
relative to what we observed with an increased slope.
It is possible that the procedures used to link the database of the
SPDP with that of the SCA could have resulted in some subjects
having been assigned incorrect exposure histories and in some
having been assigned an incorrect disease status, although we view
these as unlikely possibilities due to the checks used to verify
subjects￿ identities (Rawson et al, 1992). Such events would be
expected to be rare, and occur randomly, independent of exposure
or disease status. Their anticipated effect on our analysis would be
to bias the RRs towards the null; that is, the true RRs would be
more extreme than those we observed (Marshall et al, 1981;
Brenner and Gefeller, 1993).
Interpretation of results
The trend towards a decreasing rate ratio for colon cancer associ-
ated with increasing dose during the 6 months preceding the index
date (Table 2) may have been due to a reduced rate of dispensing
of NSAIDs among cases because of signs and symptoms caused
by undiagnosed colon cancer, e.g. rectal bleeding, anaemia,
abdominal pain. Physicians could have attributed these
phenomena to NSAIDs and advised their patients to stop using
them, or the cases could have stopped on their own. We have no
information about the proportions of cases detected with and
without symptoms. There is no formal population screening
programme for colorectal cancer in Saskatchewan.
However, the trend could also be evidence of a growth-
inhibiting effect of NSAIDs on colon tumours when they were
large enough and growing rapidly enough to cause the symptoms
that resulted in diagnosis. Such an effect could postpone diagnosis
and explain our result. Evidence for such an effect in patients with
diagnosed tumours comes from a randomized controlled trial of
anti-inflammatory therapy in undernourished patients with several
types of metastatic solid tumours (Lundholm et al, 1994). Patients
were randomized to receive either placebo, prednisolone (10 mg
twice daily), or indomethacin (50 mg twice daily). The patients
treated with indomethacin tended to maintain their overall func-
tional ability compared to those treated with placebo and to expe-
rience less pain and consume fewer analgesics. Indomethacin
prolonged mean survival compared to placebo from 250 ± 28 days
to 510 ± 28 days (P < 0.05).
The absence of a similar trend for rectal cancer could be related
to the lesser power of the analyses for that tumour, resulting from
the smaller numbers of subjects. In Table 2 there is a suggestion of
a protective effect associated with the highest level of exposure
during the period 1—6 months before diagnosis: the rate ratio was
0.80 (95% CI 0.59—1.08). Other explanations could relate to how
rectal tumours manifest symptoms and are diagnosed, as well as
their sensitivity to the effects of NSAIDs, which could differ from
that of colonic tumours.
The dose-dependent reduction in the risk of developing colon
cancer and rectal cancer associated with the dispensing of NSAIDs
11—15 years before diagnosis is unlikely to be related to chance.
Selection or recall bias were very unlikely due to the study design.
The effects of possible confounding by other determinants of
colorectal cancer such as a high fat diet, physical inactivity, heavy
beer consumption (Potter et al, 1993) and cigarette smoking
(Giovannucci et al, 1994a, 1994b) remain unknown, although
other studies did not detect confounding by these determinants
(Rosenberg et al, 1991; Giovannucci et al, 1995). The time interval
between exposure and diagnosis, the strength of the association
and the consistency with the results of animal experiments
(Pollard and Luckert, 1981; Birkenfeld et al, 1987) suggest to us
that the protective effect is genuine.
Our results are also consistent with those from other epidemio-
logical studies. Rosenberg et al (1991) found that exposure during
the year preceding diagnosis was associated with a reduced risk of
colon cancer. The duration of previous exposure did not appear to
be relevant, but the effect of the timing of exposure was not evalu-
ated. Other studies have shown a protective effect earlier in aetio-
logic time. Cohort studies have shown that appreciable aspirin use
during the month before the inception of the cohorts was associ-
ated with a reduced rate ratio 7—10 years later (Thun et al, 1991;
Gridley et al, 1993; Giovannucci et al, 1994c; Schreinemachers
and Everson, 1994). These studies, however, measured exposure
only at a single point in time: it is likely that exposure at that time
was associated with exposure previous and subsequent, before the
index date. The Nurses￿ Health Study (Giovannucci et al, 1995)
measured exposure at intervals: during 1980, 1982, 1984 and
1988. Giovannucci et al (1995) found that ‡ 10 years of regular
aspirin use (‡ 2 aspirin tablets per week) were required to observe
a protective effect. For women exposed for † 9 years the rate ratio
was 0.97 (95% Cl 0.74—1.27), whereas for exposure for ‡ 10 years
the rate ratio was 0.63 (95% CI 0.42—0.94).
Our results suggest that nine years of exposure to aspirin were
not required but that there was a 9-year delay between exposure
and the protective effect. This conclusion is supported by our
finding that NSAID exposure during the periods 2—5 and 6—10
years prior to the diagnosis of either colon or rectal cancer was not
associated with any significant trends towards protective effects,
whereas exposure 11—15 years before was.
CONCLUSION
We believe that the dose-dependent reduction in the rate ratios for
colon cancer and rectal cancer associated with the dispensing of
NSAIDs 11—15 years before the index date represents a true
protective effect. The reduction in the rate ratio for colon cancer
associated with NSAID exposure during the 6 months preceding
the index date may represent a growth inhibiting effect of NSAIDs
on already established but as yet undiagnosed cancer or a ￿reverse
causality￿ effect in which the presence of disease caused a reduc-
tion of exposure.
Our results should be considered in planning intervention trials
aimed at reducing the incidence of colorectal cancer and in evalu-
ating the results of clinical programmes recommending the use of
NSAIDs to prevent colorectal cancer. Although we cannot recom-
mend one NSAID over another, it seems evident that larger doses
are likely to be more protective than smaller doses, although dose-
related toxicity should also be considered. Intervention trials
should be planned to last at least 10 years. Negative results from68 J-P Collet et al
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trials lasting less than 10 years (Gann et al, 1993) should not be
interpreted as conclusive evidence of lack of effect — a longer dura-
tion of follow-up may be required to demonstrate a protective
effect. Once the protective effect becomes apparent after a delay of
about 10 years, it may persist if exposure is sustained.
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